ArticleThe CRISPR journal2019
A Type IV-A CRISPR-Cas System in
Article in The CRISPR journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 58 citations in OpenAlex.
- The application of the CRISPR-Cas system in Pseudomonas aeruginosa infections.Molecular biology reports · 2026Review
- Eco-evolutionary dynamics of defense systems in mobile genetic elements: Cui bono?Research square · 2026Article
- Eco-evolutionary dynamics of defense systems in mobile genetic elements: Cui bono?bioRxiv : the preprint server for biology · 2026Article
- Characterization and engineering of a type IV-A3 CRISPR-Cas system for genome editing in Escherichia coli.Nucleic acids research · 2025Article
- Type I-Fv and engineered type IV-A1 CRISPR-Cas effectors facilitate genome reduction in Escherichia coli.Nucleic acids research · 2025Article
- Article
- TIGR-Tas and the Expanding Universe of RNA-Guided Genome Editing Systems: A New Era Beyond CRISPR-Cas.Genes · 2025Review
- The extended mobility of plasmids.Nucleic acids research · 2025Review
- Bacteriophages inMicrobial genomics · 2025Article
- Developing a Versatile Arsenal: Novel Antimicrobials as Offensive Tools Against Pathogenic Bacteria.Microorganisms · 2025Review
- Structure, function and evolution of the bacterial DinG-like proteins.Computational and structural biotechnology journal · 2025Review
- Real-time imaging of bacterial colony growth dynamics for cells with Type IV-A1 CRISPR-Cas activity.microLife · 2025Article
- Determining the biochemical function of type IV CRISPR ribonucleoprotein complexes and accessory proteins.Methods in enzymology · 2025Article
- CRISPR in mobile genetic elements: counter-defense, inter-element competition and RNA-guided transposition.BMC biology · 2024Review
- Visualization of Type IV-A1 CRISPR-mediated repression of gene expression and plasmid replication.Nucleic acids research · 2024Article
- Structural variation of types IV-A1- and IV-A3-mediated CRISPR interference.Nature communications · 2024Article
- The N-terminal domain of Type IV-A1 CRISPR-associated DinG is vulnerable to proteolysis.microPublication biology · 2024Article
- Article
- Uncovering the functional diversity of rare CRISPR-Cas systems with deep terascale clustering.Science (New York, N.Y.) · 2023Article
- Characterization and diversity of CRISPR/Cas systems in Klebsiella oxytoca.Molecular genetics and genomics : MGG · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Bacteria and archaea use CRISPR-Cas adaptive immune systems to destroy complementary nucleic acids using RNAs derived from CRISPR loci. Here, we provide the first functional evidence for type IV CRISPR-Cas, demonstrating that the system from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.